July 24, 2024
Alkermes plc Reports Second Quarter 2024 Financial Results
July 17, 2024
Alkermes to Report Second Quarter Financial Results on July 24, 2024
June 03, 2024
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
We think broadly about our commitment to responsible environmental stewardship, and strive to reduce the impact of our operations on the environment. We also seek to foster a collaborative culture that promotes the health, safety and well-being of our employees.
In celebration of International Women's Day, three senior female leaders at Alkermes reflected on their career journeys and their efforts to inspire inclusion.
Our employees are the foundation upon which our business is built. Their expertise, intelligence and creativity drive our innovation, and their passion and commitment to excellence are the cornerstone of our success.
Olanzapine and samidorphan
Schizophrenia and Bipolar I Disorder (Pediatric)
Phase 3
Olanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S.
Olanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.
ALKS 2680
Narcolepsy Type 1
Phase 2
Narcolepsy Type 2
Phase 1
ALKS 2680 is an investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy.
ALKS 2680 is currently being evaluated in the Vibrance-1 phase 2 study in adults with narcolepsy type 1. For more information about this study, please visit vibrancestudies.com (for U.S. audiences only) and clinicaltrials.gov/study/NCT06358950.
ALKS 2680 was previously evaluated in a phase 1 study in healthy volunteers, and in adults with narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.
Orexin Agonists
Neuroscience Indications
Discovery
Additional orexin 2 receptor agonists are in discovery for excessive daytime sleepiness disorders and other neuropsychiatric disorders.